Corporate Report

The report describes Fuji Pharma's group sustainability activities, including a Sustainability Committee chaired by the President and a newly formulated Environmental Policy. It highlights the appointment of two female Outside Directors, a 21.3% female managerial-position ratio as of April 2021, and initiatives supporting women's health and career advancement. Financially, consolidated FY2020 net sales were 33,793 million yen, while the company continued executing its women's healthcare, biosimilar, overseas, and sustainable-growth strategies.